Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 16,130 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Atopic Dermatitis
Interventions: Dupilumab; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 12 Years and older
Enrollment: 46 participants
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Cervical Cancer, Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Lung Cancer, Prostate Cancer
Interventions: Physical Activity Promotion Intervention; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 65 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Breast Cancer
Interventions: Amcenestrant, Palbociclib, Alpelisib, Everolimus, Abemaciclib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more

Conditions: Breast Cancer, Gynecologic Cancer, Cancer-related Cognitive Difficulties
Interventions: Semiconductor embedded headband, Sham Headband; Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Melanoma (Skin)
Interventions: vinorelbine; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 86
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more

Conditions: Psoriasis
Interventions: JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Los Angeles, California • Santa Monica, California • Atlanta, Georgia + 7 more

Conditions: Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: bevacizumab, docetaxel, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 2
States / cities: Aurora, Colorado • Columbus, Ohio

Conditions: Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
Interventions: Benralizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more

Conditions: Acne Vulgaris
Interventions: CLPG Topical Gel 1%, Clindamycin, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Leg Ulcer
Interventions: ICXP007; Drug
Lead sponsor: Intercytex; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 31
States / cities: Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more

Conditions: Systemic Juvenile Idiopathic Arthritis
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 19 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 33 more

Conditions: Arthritis, Psoriatic, Psoriasis
Interventions: fludarabine; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms, Breast
Interventions: lapatinib, lapatinib plus esomeprazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Breast Cancer
Interventions: filgrastim, pegfilgrastim, lyso-thermosensitive liposomal doxorubicin(Thermodox), hyperthermia treatment; Biological · Drug · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Actinic Keratoses
Interventions: BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp; Combination Product
Lead sponsor: Biofrontera Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • Greenwood Village, Colorado • Delray Beach, Florida + 10 more

Conditions: Healthy, no Evidence of Disease, Lobular Breast Carcinoma in Situ
Interventions: letrozole, quality-of-life assessment, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 35 Years and older · Female only
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 3
States / cities: Tucson, Arizona • Rochester, Minnesota

Conditions: Dupuytren Contracture
Interventions: Radiation therapy; Radiation
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 45 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Atopic Dermatitis
Interventions: Dupixent; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Cancer, Metastatic Breast Cancer
Interventions: Values Assessment Tool; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: System; Lupus Erythematosus
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 75 Years · Female only
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Scleroderma, Dysphagia, GERD - Gastro-Esophageal Reflux Disease
Interventions: FLIP topography, Upper Endoscopy; Device · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Port-Wine Stain
Interventions: Pulsed Dye Laser, Combined Bipolar Radiofrequency&Pulsed Dye Laser; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Irvine, California

Conditions: Metastatic Breast Cancer
Interventions: Eniluracil, 5-Fluorouracil, Leucovorin, Capecitabine; Drug
Lead sponsor: Adherex Technologies, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Gilbert, Arizona • Houston, Texas

Search by objective public record fields.

Dupilumab Phase 4 Study

Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairment in Breast and Gynecological Cancer Patients

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Safety and Efficacy Study of ICXP007 With Compression Bandaging for the Treatment of Non-Infected Venous Leg Ulcers

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release

Dupixent and Narrowband UVB for Atopic Dermatitis

Adaptation of a Values Assessment Tool

Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)

Functional Luminal Imaging Probe (FLIP) Topography Use in Patients With Scleroderma and Trouble Swallowing

Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment

Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer